VANCOUVER, CanadaAd-vectus Life Sciences Inc. has begun preclinical
testing of its patented nanoparticle-based technology (Nanocure) at the
University of North Carolina Brain Tumor Center. This series of studies will
test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from
lung, breast, renal cell, and colon cancers, and melanoma, the company
P80DOX-NP is a novel method for the delivery of doxorubicin across the
blood-brain barrier. The randomized, placebo-controlled study will measure
survival as a surrogate for intracranial tumor progression/regression.